Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.81 -0.05 (-0.28%)

Delayed Quote Updated: 1:45 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

September 30, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

September 22, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

September 18, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

September 14, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

September 09, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗

August 31, 2026

One of J&J's investments stands head-and-shoulders above the rest.

Via The Motley Fool

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

August 28, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

August 24, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda (TAK) Q1 2026 Earnings Call Transcript ↗

August 07, 2026

New product launches surge 22.6% as Takeda readies three major launches.

Via The Motley Fool

Topics Earnings

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

August 05, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Pharmaceutical Q1 Earnings Call Highlights ↗

July 30, 2026

Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its...

Via MarketBeat

Topics Earnings

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

July 30, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

July 16, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

July 12, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

June 24, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

June 15, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

June 11, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

June 09, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda

May 18, 2026

From Hagens Berman

Via Business Wire

Takeda Pharmaceutical Q4 Earnings Call Highlights ↗

May 15, 2026

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around...

Via MarketBeat

Topics Earnings

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

May 13, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Novavax (NVAX) Q2 2025 Earnings Transcript ↗

May 06, 2026

Novavax (NVAX) Q2 2025 Earnings Transcript

Via The Motley Fool

Why Did Axsome Therapeutics Stock Hit Another Record High Today? ↗

May 04, 2026

Investors think a new addition to the biotech's pipeline could be the next catalyst.

Via The Motley Fool

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

May 04, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’

April 06, 2026

On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...

Via MarketMinute

The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals

March 31, 2026

Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

March 28, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

March 26, 2026

On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...

Via Finterra

Topics Economy Initial Public Offering

The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026

March 25, 2026

As of March 25, 2026, Grifols S.A. (NASDAQ: GRFS) stands at a pivotal crossroads in its century-long history. Once the undisputed champion of the European healthcare sector, the Spanish plasma giant...

Via Finterra

Topics Bankruptcy Economy Lawsuit

The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush

March 18, 2026

As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way...

Via MarketMinute

Topics Artificial Intelligence Economy

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.